Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.58 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.58 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.58 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | LIPE | Q05469 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzene SCHEMBL1720409 | 0.83 | CHRNB2 (0.59) | CHRNB2CHRNB4CHRNA3CHRNA4RAB9A | |
| SCHEMBL442790 | 0.83 | CHRNB2 (0.59) | CHRNB2CHRNB4CHRNA3CHRNA4RAB9A | |
| SCHEMBL11349063 | 0.83 | CHRNB2 (0.60) | CHRNB2CHRNB4CHRNA3CHRNA4RAB9A | |
| SCHEMBL515011 | 0.81 | CHRNB2 (0.58) | CHRNB2CHRNB4CHRNA3CHRNA4RAB9A | |
| SCHEMBL28740847 | 0.81 | CHRNB2 (0.58) | CHRNB2CHRNB4CHRNA3CHRNA4RAB9A | |
| SCHEMBL28080593 | 0.80 | CHRNB2 (0.65) | CHRNB2CHRNB4CHRNA3CHRNA4RAB9A | |
| SCHEMBL27766401 | 0.80 | CHRNB2 (0.65) | CHRNB2CHRNB4CHRNA3CHRNA4RAB9A | |
| SCHEMBL27558112 | 0.80 | CHRNB2 (0.56) | CHRNB2CHRNB4CHRNA3CHRNA4RAB9A | |
| SCHEMBL11176275 | 0.79 | CHRNB2 (0.63) | CHRNB2CHRNB4CHRNA3CHRNA4RAB9A | |
| SCHEMBL18127760 | 0.79 | CHRNB2 (0.55) | CHRNB2CHRNB4CHRNA3CHRNA4RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459561-B2 | N-substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA AG (CH) | 2008-12-02 | — | — | US | disclosed |
| US-7189858-B2 | N-phenyl substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA AG (CH) | 2007-03-13 | — | — | US | disclosed |
| US-20070027322-A1 | N-substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA INTERNATIONAL LTD. (CH) | 2007-02-01 | — | — | US | disclosed |
| US-7151182-B2 | Intermediates for N-substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA AG (CH) | 2006-12-19 | — | — | US | disclosed |
| EP-1280795-B1 | N-SUBSTITUTED CARBAMOYLOXYALKYL-AZOLIUM DERIVATIVES | BASILEA PHARMACEUTICA AG (CH) | 2005-03-23 | — | — | EP | disclosed |
| US-20050038075-A1 | Intermediates for N-substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA INTERNATIONAL LTD. (CH) | 2005-02-17 | — | — | US | disclosed |
| US-20050038038-A1 | N-phenyl substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA INTERNATIONAL LTD. (CH) | 2005-02-17 | — | — | US | disclosed |
| US-6812238-B1 | WATER SOLUBLE FUNGICIDES FOR SYSTEMIC MYCOSES; ORAL AND PARENTERAL ADMINISTRATION | BASILEA PHARMACEUTICA AG (CH) | 2004-11-02 | — | — | US | disclosed |
| EP-1280795-A2 | N-SUBSTITUTED CARBAMOYLOXYALKYL-AZOLIUM DERIVATIVES | Basilea Pharmaceutica AG (CH) | 2003-02-05 | — | — | EP | disclosed |
| WO-2001032652-A2 | N-SUBSTITUTED CARBAMOYLOXYALKYL-AZOLIUM DERIVATIVES | BASILEA PHARMACEUTICA AG (CH) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027322-A1 | N-substituted carbamoyloxyalkyl-azolium derivatives | ERG28, CYP51A1, NAALAD2 | CHRNB2 4850/4885CHRNB4 4824/4885CHRNA3 4807/4885 |
| US-20050038038-A1 | N-phenyl substituted carbamoyloxyalkyl-azolium derivatives | ERG28, CYP51A1, NAALAD2 | CHRNB2 4857/4885CHRNB4 4830/4885CHRNA3 4831/4885 |
| US-20050038075-A1 | Intermediates for N-substituted carbamoyloxyalkyl-azolium derivatives | ERG28, CYP51A1, CPS1 | CHRNB2 4841/4885CHRNB4 4849/4885CHRNA3 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.